Toward human immunodeficiency virus type-1 (HIV-1) cure, cells latently infected with HIV-1 must be eliminated from people living with HIV-1. We previously developed a protein kinase C (PKC) activator, diacylglycerol (DAG)-lactone derivative , with high HIV-1 latency-reversing activity, based on YSE028 () as a lead compound and found that the activity was correlated with binding affinity for PKC and stability against esterase-mediated hydrolysis. Here, we synthesized new DAG-lactone derivatives not only containing a tertiary ester group or an isoxazole surrogate but also several symmetric alkylidene moieties to improve HIV-1 latency reversing activity. Compound , with a dimethyl group at the α-position of the ester group, exerted twice higher HIV-1 latency reversing activity than compound , and compound , with the isoxazole moiety, was significantly active. In addition, DAG-lactone derivatives with moderate hydrophobicity and potent biostability showed high biological activity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acsinfecdis.4c00194 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!